BeBetter Med

China clinical-stage biopharma -- oncology, autoimmune, metabolic disease

688759 · SSE STAR Market · China

Public Market Listing

688759SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for BeBetter Med are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
CDK4 (selective)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
PI3K and HDAC (dual inhibition)Small molecule
Multiple MyelomaDiffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
Angiotensinogen (AGT) / PCSK9 (dual)RNA / oligonucleotide
Hypertension

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
BEBT-109Phase 2Non Small Cell Lung Cancer
Est. primary completion 2027-06 · NCT06514027 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
IfupinostatPhase 2Previously Untreated Peripheral T-Cell Lymphoma
Est. primary completion 2028-01-31 · NCT07676175 · CT.gov ↗
What to watch
November 2028 (1)
BEBT-701Phase 1/2Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
Est. primary completion 2028-11-30 · NCT07368608 · CT.gov ↗
What to watch
December 2028 (1)
IfupinostatPhase 3Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Est. primary completion 2028-12-31 · NCT06792253 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
BEBT-209Phase 2/3Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Est. primary completion 2030-06 · NCT07544056 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$17M$144M$21Mreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$17M$13M$7.8Mreport ↗
2023-FY$0——$24Mreport ↗